Skip to main content
. 2019 Oct 15;11(10):1562. doi: 10.3390/cancers11101562

Table A1.

Univariate Cox proportional hazards model analysis of survival for each cancer type included in the study.

Cancer Types Label Number of Samples HR 95% CI for HR p Value
UVM TMB/TGF-β score positive n = 80 0.3 0.04–2.2 0.24
SKCM TMB/TGF-β score positive n = 103 0.45 0.11–2 0.29
GBM TMB/TGF-β score positive n = 146 0.69 0.28–1.7 0.42
LIHC TMB/TGF-β score positive n = 349 1 0.59–1.8 0.91
SARC TMB/TGF-β score positive n = 201 0.85 0.41–1.8 0.66
PCPG TMB/TGF-β score positive n = 177 4.9 0.8–30 0.085
TCGT TMB/TGF-β score positive n = 127 1.5 0.89–2.6 0.12
THCA TMB/TGF-β score positive n = 481 0.87 0.11–6.7 0.89
PAAD TMB/TGF-β score positive n = 146 1 0.53–1.9 0.96
PRAD TMB/TGF-β score positive n = 410 3 0.74–12 0.12
UCEC TMB/TGF-β score positive n = 542 0.25 0.092–0.69 0.007
CHOL TMB/TGF-β score positive n = 35 2.2 0.69–7 0.18
KICH TMB/TGF-β score positive n = 64 6.4 1.6–26 0.0091
BLCA TMB/TGF-β score positive n = 412 0.67 0.42–1.1 0.096
KIRP TMB/TGF-β score positive n = 266 0.27 0.064–1.1 0.071
HNSC TMB/TGF-β score positive n = 488 1.1 0.8–1.6 0.48
CESC TMB/TGF-β score positive n = 282 0.48 0.19–1.2 0.11
BRCA TMB/TGF-β score positive n = 1009 0.94 0.57–1.6 0.81
OV TMB/TGF-β score positive n = 164 0.67 0.31–1.4 0.31
LGG TMB/TGF-β score positive n = 499 0.87 0.38–2 0.74
LUAD TMB/TGF-β score positive n = 492 0.58 0.33–1 0.05
ESCA TMB/TGF-β score positive n = 151 1.3 0.65–2.7 0.45
READ TMB/TGF-β score positive n = 125 0.86 0.19–3.9 0.85
LUSC TMB/TGF-β score positive n = 484 0.79 0.52–1.2 0.28
COAD TMB/TGF-β score positive n = 462 0.73 0.39–1.4 0.33
UCS TMB/TGF-β score positive n = 56 1.1 0.4–3.3 0.8
MESO TMB/TGF-β score positive n = 76 0.5 0.21–1.2 0.11
ACC TMB/TGF-β score positive n = 78 6.4 2.3–18 4 ×10−4
STAD TMB/TGF-β score positive n = 345 0.62 0.35–1.1 0.088

Abbreviations of cancer cohort: adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal papillary cell carcinoma (KIRP), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), mesothelioma (MESO), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), sarcoma (SARC), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), testicular germ cell tumors (TGCT), thyroid carcinoma (THCA), uterine corpus endometrial carcinoma (UCEC), uterine carcinosarcoma (UCS) and uveal melanoma (UVM).